Glecaprevir; pibrentasvir - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for glecaprevir; pibrentasvir and what is the scope of freedom to operate?
Glecaprevir; pibrentasvir
is the generic ingredient in one branded drug marketed by Abbvie and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Glecaprevir; pibrentasvir has five hundred and thirty patent family members in forty-six countries.
One supplier is listed for this compound.
Summary for glecaprevir; pibrentasvir
International Patents: | 530 |
US Patents: | 10 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 31 |
DailyMed Link: | glecaprevir; pibrentasvir at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for glecaprevir; pibrentasvir
Generic Entry Dates for glecaprevir; pibrentasvir*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
Generic Entry Dates for glecaprevir; pibrentasvir*:
Constraining patent/regulatory exclusivity:
Dosage:
PELLETS;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for glecaprevir; pibrentasvir
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
White River Junction Veterans Affairs Medical Center | Phase 2 |
Peking University People's Hospital | Phase 4 |
White River Junction Veterans Affairs Medical Center | Phase 2/Phase 3 |
Pharmacology for glecaprevir; pibrentasvir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Abbvie | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Abbvie | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for glecaprevir; pibrentasvir
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AbbVie Deutschland GmbH Co. KG | Maviret | glecaprevir, pibrentasvir | EMEA/H/C/004430 Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older. |
Authorised | no | no | no | 2017-07-26 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for glecaprevir; pibrentasvir
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3020723 | DÉRIVÉS DE PROLINES MACROCYCLIQUES INHIBITEURS DE LA SÉRINE PROTÉASE DU VHC (MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS) | ⤷ Try a Trial |
Canada | 2901810 | COMBINAISON DE DEUX ANTIVIRAUX POUR LE TRAITEMENT DE L'HEPATITE C (COMBINATION OF TWO ANTIVIRALS FOR TREATING HEPATITIS C) | ⤷ Try a Trial |
Japan | 2018518517 | HCVを処置するための固体医薬組成物 | ⤷ Try a Trial |
Japan | 5911838 | ⤷ Try a Trial | |
European Patent Office | 3140284 | FORMES CRISTALLINES (CRYSTAL FORMS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for glecaprevir; pibrentasvir
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2368890 | CR 2015 00015 | Denmark | ⤷ Try a Trial | PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150119 |
2618831 | 17C1039 | France | ⤷ Try a Trial | PRODUCT NAME: GLECAPREVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN ESTER DE CELUI-CI; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
2618831 | 300 50016-2017 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: GLECAPREVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
2368890 | 639 | Finland | ⤷ Try a Trial | |
2692346 | 2017/046 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.